Insulin Titration for Persistent Hyperglycemia

Basal Insulin Titration

• Increase basal insulin glargine by 2 units every 3 days until fasting plasma glucose reaches 100–120 mg/dL (5.5–6.7 mmol/L), monitoring daily to avoid hypoglycemia. 1
• If a fasting glucose < 70 mg/dL occurs, reduce the basal dose by 10–20 %. [1][2]
• Do not exceed 0.5–1.0 units/kg/day of basal insulin without achieving target; consider adding a GLP‑1 receptor agonist instead of further escalation. 1

Prandial (Rapid‑Acting) Insulin Adjustment

• Increase each prandial dose by 1–2 units or 10–15 % of the current dose to correct post‑prandial hyperglycemia. 2
• Titrate prandial insulin based on 2–4 hour post‑prandial glucose values; prioritize the meal with the greatest glucose excursion. 2
• Once fasting glucose is in target, add 1–2 units to meals where the 2‑hour post‑prandial glucose exceeds goal. 2

Estimating Total Daily Insulin Requirements

• For insulin‑naïve or low‑dose patients, the total daily dose (TDD) is approximately 0.3–0.5 units/kg/day. 3
• The basal component should comprise roughly 50 % of the TDD (≈ 0.2 units/kg), with the remaining 50 % allocated to prandial doses divided among three meals. 3

Monitoring and Safety

• Daily fasting glucose checks are required during basal titration. [1][4]
• Any glucose reading < 70 mg/dL mandates a 10–20 % dose reduction of the offending insulin. [1][4]2
• An elevated bedtime‑to‑morning glucose differential signals inadequate basal coverage; a high post‑prandial‑to‑pre‑prandial differential indicates the need for prandial dose adjustment. 1

Therapeutic Strategies and Pitfalls

• Avoid sliding‑scale insulin alone in patients already on basal‑bolus regimens; it is associated with poorer glycemic control. 3
• Prevent therapeutic inertia: if glucose remains above target for ≥ 3 days, increase the appropriate insulin dose rather than waiting weeks. [1][5]
• Reassess the insulin regimen every 3–6 months to ensure continued efficacy and safety. [1][5]

Adjunctive Therapy with GLP‑1 Receptor Agonists

• When A1C remains above goal despite optimized insulin titration, add a GLP‑1 receptor agonist before further insulin escalation; this strategy reduces hypoglycemia risk and can improve overall outcomes. [1][5]

Overbasalization Threshold and Assessment of Basal Insulin Adequacy

Dose Appropriateness

• In patients treated with basal insulin glargine, doses that exceed 0.5 units/kg/day are linked to overbasalization; a regimen of 27 units daily (approximately 0.4 units/kg for an average adult) is therefore considered appropriate and does not demonstrate overbasalization【6】.

Clinical Indicators of Basal Coverage

• An elevated bedtime‑to‑morning glucose differential may indicate inadequate basal insulin effect, but when fasting glucose values remain within the target range, this differential is less concerning and suggests that basal coverage is adequate【6】.

Intensifying Therapy for Adults with Type 2 Diabetes and Elevated A1C

Immediate Treatment Intensification

• In adults with type 2 diabetes and an A1C of ≈ 9 % (well above target), therapeutic inertia should be avoided and a full basal‑bolus insulin regimen must be initiated promptly. 7
• The American Diabetes Association (2025) recommends starting rapid‑acting insulin at ≈ 4 units per meal (or ≈ 10 % of the total daily dose) when converting to a basal‑bolus schedule. 7

Integration of GLP‑1 Receptor Agonists

• Before basal insulin exceeds 0.5 units/kg/day, a GLP‑1 receptor agonist with proven cardiovascular benefit should be added to the regimen. 7
• Adding a GLP‑1 RA to basal‑bolus therapy lowers A1C by an additional 1.0–2.0 percentage points. 7
• GLP‑1 RA therapy reduces the risk of hypoglycemia compared with further insulin dose escalation alone. 7
• Independent of glycemic effects, GLP‑1 RAs provide cardiovascular and renal protection. 7
• GLP‑1 RAs mitigate insulin‑associated weight gain. 7
• The ADA 2025 guidelines give a strong recommendation for using GLP‑1 RAs in patients not at glycemic goal before further insulin intensification. 7
• Combining a GLP‑1 RA with a DPP‑4 inhibitor offers no additive glucose‑lowering benefit and should be avoided. 7

Expected Glycemic Outcomes

• Proper titration of a basal‑bolus regimen is expected to reduce A1C by ≈ 1.5–2.0 percentage points from baseline. 7
• When a GLP‑1 RA is added, an additional ≈ 1.0–2.0 percentage‑point A1C reduction can be achieved. 7

Practical Implementation Algorithm (Evidence‑Based Steps)

• Day 1: Initiate basal insulin (long‑acting analog) at 0.2–0.3 units/kg once daily in the morning and continue rapid‑acting insulin ≈ 4 units before each meal. 7
• Days 1–14: Titrate basal insulin by 2 units every 3 days, targeting fasting glucose 100–120 mg/dL. (Evidence from same guideline.)
• Week 2: Add a cardiovascular‑benefit GLP‑1 RA (e.g., semaglutide, dulaglutide, liraglutide). 7
• Weeks 2–8: Adjust prandial insulin by 1–2 units per meal based on 2‑hour post‑prandial glucose values. (Guideline‑derived practice.)
• Week 8: Re‑measure A1C; if still > 7 %, continue titration but do not exceed 0.5 units/kg/day total insulin without re‑evaluating the regimen. (Guideline‑derived practice.)

Avoiding Critical Pitfalls (Cited Guidance)

• Delaying intensification for ≥ 3 days while glucose remains above target constitutes therapeutic inertia and should be avoided. 7